GlassScriptPhysician profile
Heather Nicole Nickell
NPI 1386256717
$1,822.64
in general payments reported to CMS, 2019-2025
27 companies · $574 in 2025
The $574 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $214 · 2024: $1,035 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.70 |
| Education | $268.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $295.59 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $212.15 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $193.08 | 2023-2025 | Imfinzi, Tagrisso, Calquence |
| Incyte Corporation | $148.47 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $133.99 | 2024-2025 | |
| Stemline Therapeutics INC. | $131.49 | 2024 | Orserdu |
| Aveo Pharmaceuticals, INC. | $110.95 | 2024-2025 | |
| Abbvie INC. | $66.28 | 2024-2025 | |
| Lilly USA, LLC | $52.84 | 2024 | Jaypirca, Retevmo, Verzenio |
| Array Biopharma INC | $49.02 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Janssen Biotech, INC. | $48.91 | 2024-2025 | Erleada, Balversa, Akeega |
| Daiichi Sankyo INC. | $45.12 | 2024 | Enhertu |
| Genentech USA, INC. | $38.40 | 2024-2025 | Tecentriq |
| Regeneron Healthcare Solutions, INC. | $31.51 | 2024-2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $29.20 | 2024-2025 | Ultomiris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $27.54 | 2025 | Mi Cancer Seek |
| Eisai INC. | $27.28 | 2024 | |
| Amgen INC. | $26.55 | 2024 | Uplizna, Evenity, Prolia |
| Servier Pharmaceuticals LLC | $20.66 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.55 | 2023 | |
| Pharmaessentia USA Corporation | $19.86 | 2024 | Besremi |
| Mirati Therapeutics, INC. | $17.58 | 2024 | Krazati |
| Genzyme Corporation | $16.22 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.98 | 2024 | Krazati |
| Glaxosmithkline, LLC. | $15.57 | 2025 | Ojjaara |
| Geron Corporation | $14.14 | 2025 | Rytelo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.71 | 2023 | Trulance, Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Nickell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.